InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-46.6%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by WORLAND STEPHEN T, Chairman & CEO. Director active across 1 company, notably eFFECTOR Therapeutics, Inc.. Aggregated, 9 disclosures have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €26k. History available since 13 May 2022. The latest transaction was filed on 15 May 2024 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations9 total
1,806 shares@ US$1.6835.0% of flowCommon StockSEC:0000950170-24-061593:0
5,979 shares@ US$0.49734.9% of flowCommon StockSEC:0001209191-23-055557:0
33,799 shares@ US$0.5228.9% of flowCommon StockSEC:0001209191-23-045499:0
6,401 shares@ US$0.4594.9% of flowCommon StockSEC:0001209191-23-029646:0
6,047 shares@ US$0.46845.0% of flowCommon StockSEC:0001209191-22-057379:0
20,000 shares@ US$1.3790.4% of flowCommon StockSEC:0001209191-22-035277:0
Ideal exit: 4 Mar 2023 (T+270)
1,837 shares@ US$1.539.6% of flowCommon StockSEC:0001209191-22-029890:0
512,339 sharesCommon StockSEC:0001209191-21-053686:0
512,339 sharesCommon StockSEC:0001209191-21-053686
9 of 9 declarations
About WORLAND STEPHEN T
Worland Stephen T is the Chairman and CEO of eFFECTOR Therapeutics, Inc. He leads the company with a focus on developing innovative therapies for cancer treatment. His leadership and strategic vision are essential in guiding eFFECTOR's research and development efforts aimed at improving patient outcomes.
